TWI478915B - 宿主防禦之合成模擬物及其用途 - Google Patents

宿主防禦之合成模擬物及其用途 Download PDF

Info

Publication number
TWI478915B
TWI478915B TW098136112A TW98136112A TWI478915B TW I478915 B TWI478915 B TW I478915B TW 098136112 A TW098136112 A TW 098136112A TW 98136112 A TW98136112 A TW 98136112A TW I478915 B TWI478915 B TW I478915B
Authority
TW
Taiwan
Prior art keywords
compound
formula
gram
pyrimidine
halo
Prior art date
Application number
TW098136112A
Other languages
English (en)
Chinese (zh)
Other versions
TW201020249A (en
Inventor
William F Degrado
Dahui Liu
Richard W Scott
Yongjiang Xu
Haizhong Tang
Bozena Korczak
Original Assignee
Cellceutix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellceutix Corp filed Critical Cellceutix Corp
Publication of TW201020249A publication Critical patent/TW201020249A/zh
Application granted granted Critical
Publication of TWI478915B publication Critical patent/TWI478915B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW098136112A 2008-10-27 2009-10-26 宿主防禦之合成模擬物及其用途 TWI478915B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10859508P 2008-10-27 2008-10-27

Publications (2)

Publication Number Publication Date
TW201020249A TW201020249A (en) 2010-06-01
TWI478915B true TWI478915B (zh) 2015-04-01

Family

ID=42118100

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098136112A TWI478915B (zh) 2008-10-27 2009-10-26 宿主防禦之合成模擬物及其用途

Country Status (14)

Country Link
US (2) US8278309B2 (https=)
EP (1) EP2358380A4 (https=)
JP (1) JP2012506908A (https=)
KR (1) KR20110074995A (https=)
CN (1) CN102256614B (https=)
AU (1) AU2009320139B2 (https=)
BR (1) BRPI0920251A2 (https=)
CA (1) CA2741764A1 (https=)
IL (1) IL212275A0 (https=)
MX (1) MX2011004360A (https=)
RU (1) RU2540077C2 (https=)
TW (1) TWI478915B (https=)
UA (1) UA104875C2 (https=)
WO (1) WO2010062573A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
EP2709619B1 (en) * 2011-05-16 2017-10-11 Cellceutix Corporation Compounds for use in treatment of mucositis
US9758607B2 (en) 2013-10-10 2017-09-12 Research Foundation Of The City University Of New York Polymer with antibacterial activity
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬
CN107574581B (zh) * 2017-08-03 2019-09-10 天津大学 一种抗菌性聚(ε-己内酯)/模拟抗菌肽电纺纤维膜及其制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021248008A1 (en) * 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083256A2 (en) * 2006-12-29 2008-07-10 Polymedix, Inc. Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
DK0629347T3 (da) 1992-01-23 1998-02-16 Morinaga Milk Industry Co Ltd Antibakterielt middel og behandling af genstande dermed
DE69907476T2 (de) 1998-08-20 2004-04-15 The University Of North Carolina At Chapel Hill Office Of Technology Development Dibenzothiophene derivate und ihre verwendung
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
EP3045168A1 (en) 2000-11-08 2016-07-20 FXS Ventures, LLC Improved ophthalmic and contact lens solution
EP2289524A1 (en) 2001-03-08 2011-03-02 The Trustees Of The University Of Pennsylvania Facially amphiphillic polymers as anti-infective agents
WO2003045307A2 (en) 2001-11-21 2003-06-05 Sugen, Inc. Pharmaceutical formulations comprising indolinone derivatives
CA2487454A1 (en) 2002-05-28 2003-12-04 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
EP1513622A4 (en) 2002-06-13 2005-09-14 Univ Pennsylvania METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR STIMULATING BIOMEMBRANES USING ROUGH GRAIN MODELS
EP2471526A3 (en) 2003-03-17 2012-12-12 The Trustees Of The University Of Pennsylvania Facially amphiphillic polymers and oligomers and uses thereof
AU2003249114A1 (en) 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
US20050065091A1 (en) 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
CN1922133A (zh) 2004-01-23 2007-02-28 宾夕法尼亚州大学理事会 表面两亲性聚芳基和聚芳基炔基聚合物和低聚物及其用途
PL2708225T3 (pl) 2004-04-23 2019-07-31 Cydex Pharmaceuticals, Inc. Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
AU2005254574B2 (en) 2004-06-15 2012-02-02 Polymedix, Inc. Polycationic compounds and uses thereof
JP5027659B2 (ja) 2004-07-23 2012-09-19 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗菌コポリマーおよびその使用
DK2377557T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US20100048498A1 (en) 2004-12-21 2010-02-25 Johnson Barbara A Stable non-dihydrate azithromycin oral suspensions
US20060241052A1 (en) 2005-02-25 2006-10-26 Degrado William F Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
RU2325151C2 (ru) * 2006-06-29 2008-05-27 ООО "Научно-производственный центр "Амфион" Способ получения системы доставки водонерастворимых и плохорастворимых биологически активных веществ и лекарственная форма на ее основе
JP2008137978A (ja) 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
RU2530899C2 (ru) 2008-07-28 2014-10-20 Селлсьютикс Корпорейшн Противомалярийные соединения
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083256A2 (en) * 2006-12-29 2008-07-10 Polymedix, Inc. Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof

Also Published As

Publication number Publication date
RU2011121354A (ru) 2012-12-10
MX2011004360A (es) 2011-08-12
KR20110074995A (ko) 2011-07-05
UA104875C2 (uk) 2014-03-25
TW201020249A (en) 2010-06-01
CN102256614A (zh) 2011-11-23
RU2540077C2 (ru) 2015-01-27
CN102256614B (zh) 2014-01-08
IL212275A0 (en) 2011-06-30
AU2009320139B2 (en) 2013-07-25
AU2009320139A1 (en) 2010-06-03
CA2741764A1 (en) 2010-06-03
US20100105703A1 (en) 2010-04-29
EP2358380A1 (en) 2011-08-24
US8278309B2 (en) 2012-10-02
EP2358380A4 (en) 2012-05-02
JP2012506908A (ja) 2012-03-22
US8975262B2 (en) 2015-03-10
US20130090345A1 (en) 2013-04-11
WO2010062573A1 (en) 2010-06-03
BRPI0920251A2 (pt) 2016-01-05

Similar Documents

Publication Publication Date Title
TWI478915B (zh) 宿主防禦之合成模擬物及其用途
EP2413974B1 (en) Conjugated antimicrobial agents
KR20170113529A (ko) 비-베타 락탐 항생제
US20100261639A1 (en) Triazole-based aminoglycoside-peptide conjugates and methods of use
US6841661B2 (en) Glycopeptide antibacterial compounds, compositions containing same and methods of using same
US20050107423A1 (en) Quinolone antibacterial agents
KR101653570B1 (ko) 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
US20190038759A1 (en) Cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide
JP6643484B2 (ja) 7−オキソ−6−(スルホオキシ)−1,6−ジアザビシクロ[3.2.1]オクタン−2−カルボキサミド含有化合物および細菌感染症の治療におけるそれらの使用
US11149046B2 (en) Antibacterial sideromycins
US20020045574A1 (en) Glycopeptide antibacterial compounds and methods of using same
US11014891B2 (en) Reduction-triggered antibacterial sideromycins
AU2017351906A1 (en) Functional derivative compounds of alanine and proline amino acids and pharmaceutical composition comprising same
US9353072B2 (en) Antimicrobial substituted thiazoles and methods of use
US20080132500A1 (en) Antibiotic compounds
CN120152726A (zh) 用于处置或预防中枢神经系统损伤疾病的环状肽衍生物组合物
US20170355671A1 (en) Peripherally substituted monocyclic beta-lactams
US20050119231A1 (en) Quinolone antibacterial agents
US20210163521A1 (en) Amphiphilic aminoglycoside connexin hemichannel inhibitors
KR102354697B1 (ko) 항박테리아 화합물로서의 헤테로고리 유도체
US20260027191A1 (en) Compositions and methods for treating bacterial disease
CN118974031A (zh) 抗菌剂4,5二芳基-噻吩-2-基六氟丙-2-醇
JP2009096717A (ja) 新規ヒドロキサム酸誘導体